Discussion
GG1 disease, HGPC, prostate cancer, Prostate
RECURRENCE, PROSTATE, PROSTATE, LOCALIZED DISEASE, PROSTATE CANCER
Evidence from a previously reported prospective randomized, clinical utility study established that the ExoDx Prostate (EPI) test significantly impacts prostate biopsy decisions [Patients from the EPI and SOC arms were combined and split into two groups based on the initial EPI risk assessment of low- or high-risk for HGPC ( ≥ GG2), using the previously established risk threshold of 15.6 [A key context to understanding EPI low-risk results is the fact that nearly all patients with subsequent diagnosis of GG1 disease will have favorable long-term mortality outcomes [During the study period, there was limited use of mpMRI (22%) and no use of PSMA imaging in this cohort. Thus, this reflects the reality of implementing a clinical follow-up research program as medical practice evolves. In current practice, mpMRI is more prevalent and accepted in early prostate cancer detection, but PSMA imaging is not used pre-diagnosis. Moreover, F-18 piflufolastat and Ga-68 PSMA-11 are indicated for post-treatment biochemical recurrence or unfavorable intermediate- or high-risk localized disease [